Angel Brett G, Saltzman Heath, Kusmirek Luke S
Division of Cardiology, Hahnemann University Hospital, Drexel University College of Medicine, 245 North 15th Street, Suite 6122, Philadelphia, PA, 19102, USA.
Curr Cardiol Rep. 2017 Sep 25;19(11):114. doi: 10.1007/s11886-017-0914-2.
Medical devices have become an integral part of comprehensive heart failure management. Not all heart failure patients, however, accrue benefit from every new device, and even with extensive practice guidelines, this remains an evolving field.
The addition of implantable devices, like internal cardioverter defibrillators (ICDs), and novel pacing technologies, including cardiac resynchronization therapy (CRT), have helped to compliment goal-directed medical therapy and positively impact prognosis in multiple high-quality clinical trials. This review attempts to summarize the rapidly evolving literature with respect to existing device guidelines for routine implantable devices as well as some available and future technologies that are not yet a part of routine guidelines. ICD, CRT, and other implantable devices continue to save lives, decrease hospitalizations, and evolve the management of patients with heart failure beyond the capabilities of optimal guideline-directed medical therapy alone.
医疗设备已成为心力衰竭综合管理不可或缺的一部分。然而，并非所有心力衰竭患者都能从每一种新设备中获益，即便有详尽的实践指南，这仍是一个不断发展的领域。
植入式设备（如植入式心脏复律除颤器[ICD]）以及新型起搏技术（包括心脏再同步治疗[CRT]）的加入，有助于补充目标导向的药物治疗，并在多项高质量临床试验中对预后产生积极影响。本综述试图总结关于常规植入式设备现有设备指南以及一些尚未成为常规指南一部分的现有和未来技术的快速发展的文献。ICD、CRT和其他植入式设备继续挽救生命、减少住院次数，并超越单纯最佳指南导向药物治疗的能力，改善心力衰竭患者的管理。
